Applied DNA Corp - APDN Earnings per share for the last 12 months

Applied DNA Sciences (APDN) debt load is linked to the costs of supplying molecular tags and PCR components for the textile and pharmaceutical sectors. Measuring the annual growth of EPS TTM visualizes the impact of these expenses, where the value of 21.80 expresses the metric level. Optimization is being driven through the implementation of LineaRx, growth in B2B orders, and the scaling of DNA synthesis for recurring contracts in biopharmaceuticals.
Applied DNA Corp - analytical breakdowns and key metrics (APDN)

Applied DNA Sciences (APDN) monetizes DNA technologies within the anti-counterfeiting and medical diagnostics sectors. The effectiveness of this diversification is reflected in the calculation of the difference between current and prior-year earnings per share. This indicator measures the rate of change in profitability over twelve months, revealing capital sensitivity to the Fed's tight monetary policy. The current value of 21.80 allows for an assessment of the issuer's financial stability. Analyzing the YoY ttm growth of net income per share helps identify whether the stock is overvalued or undervalued in a timely manner.